Grateful for Community đź’• KSTP News Feature

Nov 16, 2022
Image
kstp why we give

Thanks to Kevin Doran at KSTP for shining your #whywegive spotlight on the Minneapolis Heart Institute Foundation (MHIF)!

MHIF is grateful for a community of people – patients, physicians, researchers, donors and community partners – who believe in world-class heart research and education.

This work is only possible because of community support. 

This year, MHIF celebrated 40 years of a mission that puts patients at the center of the work. There is no better inspiration in this work than grateful patients and the physicians who are dedicated to the research to answer, “what can we do better?”

As you think about your year-end giving, we hope you find meaning in making a life-saving gift that will make an impact for generations to come. We are grateful for your partnership in creating a world without heart and vascular disease.

Link to original KSTP story

Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.